Go to the profile of Pacific Edge

Pacific Edge

 

About Pacific Edge

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic tests for better detection and monitoring of cancer. The company is developing and commercializing its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies. Pacific Edge has two proprietary, novel, accurate, molecular diagnostic products in-market providing more accurate, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia and has initiated launch in the USA in July 2015.

Therapeutic Areas

Oncology

Technologies

Diagnostics

Company Type

Biotechnology – Diagnostics

State of Ownership

Public

Influencer Of

Topics

Topics contributed to:

Diagnostics/Precision Medicine

Editions participated in:

Medtech May 2018 September 2018